PROFESSIONAL EDITION

The largest community of pharma leaders

BioAtla and BeiGene Revise Global Development and Commercialization Agreement for Novel Conditionally Active Biologic CTLA-4 Candidate BA3071

SAN DIEGO & BEIJING & CAMBRIDGE, Mass.–(BUSINESS WIRE)—- $BGNE #BGNE–BeiGene will hold an exclusive license to the global clinical development and commercialization of BioAtla’s investigational CAB CTLA-4 antibody.

Source

Recent Articles